European Innovation Council

Brevel develops innovative cultivation technology for sustainable, low-cost production of microalgae. Its high-tech, indoor, automated systems use internal illumination to achieve over 90% cost reduction and up to 200 times higher yields compared to traditional methods. Brevel targets various markets where microalgae-derived products are in demand.

Precisionlife employs a unique approach to drive innovation in chronic diseases through precision medicine. It uses artificial intelligence to generate deep insights into disease biology, stratifying patient populations for novel drug targets, biomarkers, and repositioning candidates.

Founded in 2012, Stablepharma specializes in developing processes for vaccine stabilization. Its flagship product, Stablevax, enables precise dosage pre-loading into syringes at manufacture, eliminating wastage. The company's technology platform converts existing vaccines and diagnostics into thermostable products, addressing global cold chain challenges.

AlzeCure Pharma is a Swedish pharmaceutical company dedicated to developing drug therapies targeting diseases affecting the central nervous system. Its primary focus lies in Alzheimer's disease, with five drug candidates at various stages of development.

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden that focuses on developing innovative cell and gene therapies to treat cancer. The company’s portfolio includes four drug candidates: two oncolytic virus therapies, ELC-100 and ELC-201, and two CAR T-cell treatments, ELC-301 and ELC-401. Additionally, Elicera has developed a universal CAR T-cell technology platform named iTANK (ELC-001), designed to enhance the efficacy of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors. With its commitment to advancing immune-based cancer treatments, Elicera Therapeutics aims to improve outcomes for patients facing various forms of cancer.

Aplagon is a biopharmaceutical company focused on the development of innovative antithrombotic compounds aimed at addressing unmet medical needs in patients experiencing complications from vascular interventions. The company specializes in creating biological mimetics of heparin proteoglycan, which are designed to effectively manage thrombotic occlusions and ischemic reperfusion injuries associated with vascular injuries. By prioritizing safety and efficacy, Aplagon seeks to deliver antithrombotic therapies that offer significant advantages over existing treatments, ultimately improving patient outcomes in challenging medical scenarios.

Oryl Photonics specializes in developing laboratory instruments for pharmaceutical and biotech companies. Their core product provides a simple, reliable, and cost-effective method for measuring solubility, contributing to accelerated drug development and improved medicine. The company's unique technology preserves valuable substances during testing, offering a solubility measurement service that empowers researchers to make data-driven decisions and expedite product development.

MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.

MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

King's College London is a public research university in London, United Kingdom, and a constituent college of the University of London. Founded in 1829 by King George IV and the Duke of Wellington, it operates from multiple central London campuses and a campus in Denmark Hill, with a strong emphasis on medical and biomedical research and education. The institution supports a large community of students and staff and is known for its extensive graduate and postgraduate programmes. It is a founding member of the King's Health Partners academic health sciences centre and participates in major research and academic networks, including the Russell Group and Universities UK.

RS Research is a clinical-stage biotechnology company focused on developing nanomedicines for cancer treatment. Based in Istanbul, Turkey, it has developed a proprietary Sagitta drug-delivery platform that enables targeted chemotherapies across multiple indications. The company advances a portfolio of nanomedicine candidates through preclinical and clinical stages, with its lead program RS-0139 studied in Phase I oncology trials and supported by a GMP-certified production facility for clinical batch drug candidates. RS Research collaborates with international partners on co-development projects and offers ancillary services such as preclinical absorption, distribution, metabolism, and excretion testing, bioanalytical method development and validation, impurity and metabolite analysis, stability testing, toxicology studies, and patent-related due diligence and drafting support. The business aims to deliver targeted therapies with improved therapeutic indices through its nanocarrier technology and partnerships.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Palobiofarma is a Spanish biotechnology company based in Barcelona, focused on discovering and developing new medicines by modulating adenosine receptors. It aims to be a leader in European adenosine receptor drug discovery, using medicinal chemistry and in vitro pharmacology to identify selective adenosine receptor modulators, with potential applications in treating advanced prostate cancer.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

ResoTher Pharma is a privately held biotechnology company based in Copenhagen, Denmark. The company specializes in developing peptide-based drugs derived from Annexin A1, an endogenous immunomodulator. These drugs are designed as resolution therapies for diseases where neutrophil-driven inflammation is a key pathological factor. ResoTher Pharma's primary focus is on addressing cardiovascular and inflammatory disorders that have significant unmet medical needs. Their patented peptide drugs target a G-protein coupled receptor expressed on leukocytes, aiming to mimic the body's natural response to resolving inflammation and promoting tissue repair.

Pasqal SAS, founded in 2019 and headquartered in Paris, France, specializes in the manufacture of quantum information processors utilizing atomic arrays. The company focuses on developing full-stack quantum computing technology that simulates complex phenomena to facilitate scientific discovery. Its innovative approach employs qubits made of neutral atoms organized in large two-dimensional and three-dimensional arrays, which enables analog computing. This technology addresses a variety of challenges, including optimization, drug discovery, and machine learning, empowering organizations to tackle complex problems across these fields.

Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Elgan Pharma is a biotechnology company specializing in neonatology, primarily focused on addressing the medical challenges faced by premature infants. The company develops innovative therapies using nanotechnology aimed at preventing visual impairment, a significant concern for preterm babies. By targeting the multifactorial causes of visual disabilities, Elgan Pharma enables healthcare professionals to improve visual outcomes and reduce the risk of long-term disabilities in this vulnerable population. Through its advancements in late-stage development, the company is committed to enhancing the quality of care for premature infants and addressing critical developmental difficulties associated with their early birth.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, focused on the development and manufacturing of therapeutic proteins aimed at restoring blood clotting in patients experiencing bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X that can promptly reinstate blood clotting in patients using direct factor Xa anticoagulants, such as rivaroxaban, apixaban, and edoxaban. These anticoagulants, commonly prescribed for the prevention and treatment of thrombosis and stroke, often lead to severe bleeding as a side effect. PseudoXa addresses this critical issue by effectively stopping and preventing bleeding, thereby enhancing the safety of anticoagulant therapy for millions of patients worldwide.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

Tada Group AB, founded in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacturing of medical products, primarily focusing on intravenous solutions. The company offers products such as the Thoor infusion tube, which is designed for efficiency in medical applications. Additionally, Tada Group has developed the ReLink connector, an innovative solution aimed at minimizing complications and costs related to accidental disconnections in IV lines, which is a significant issue in both hospital and homecare environments. Through its product offerings, Tada Group addresses critical challenges in healthcare, enhancing safety and reliability in infusion practices.

Founded in 2019, Arthex Biotech is a Spanish biotechnology company specializing in the development of antisense RNA therapies for genetic diseases. The company, spun off from the University of Valencia, leverages its team's expertise in drug discovery and microRNAs to create innovative treatments.

Smart Immune is a clinical‑stage biotechnology company developing next‑generation hematopoietic stem cell–based biotherapies to improve outcomes for patients with severe diseases. Its flagship program uses T‑cell progenitors (ProTcells) to enable rapid, polyclonal, and safe immune reconstitution after transplantation. The platform integrates targeted conditioning, gene therapy, and genome editing to extend treatment options for inherited blood disorders, blood cancers, and other life‑threatening conditions.

Smart Immune is a clinical‑stage biotechnology company developing next‑generation hematopoietic stem cell–based biotherapies to improve outcomes for patients with severe diseases. Its flagship program uses T‑cell progenitors (ProTcells) to enable rapid, polyclonal, and safe immune reconstitution after transplantation. The platform integrates targeted conditioning, gene therapy, and genome editing to extend treatment options for inherited blood disorders, blood cancers, and other life‑threatening conditions.

Nemysis is a Dublin-based specialty pharmaceutical company focused on developing and manufacturing food supplements, medical matrix products and prescription medicines. Founded in 2005, it pursues a staged development strategy to commercialize OTC and prescription products across different market segments addressing nutritional disorders and deficiencies. The company develops products such as a novel nanoparticulate oral iron supplement with a unique absorption mechanism to treat iron deficiency or anemia while minimizing gastrointestinal side effects, and glutenase capable of functioning in both the stomach and intestine to protect individuals with celiac disease or gluten sensitivity from inadvertent gluten exposure.

Pasqal SAS, founded in 2019 and headquartered in Paris, France, specializes in the manufacture of quantum information processors utilizing atomic arrays. The company focuses on developing full-stack quantum computing technology that simulates complex phenomena to facilitate scientific discovery. Its innovative approach employs qubits made of neutral atoms organized in large two-dimensional and three-dimensional arrays, which enables analog computing. This technology addresses a variety of challenges, including optimization, drug discovery, and machine learning, empowering organizations to tackle complex problems across these fields.

Founded in 2022, Kvantify is headquartered in Copenhagen, Denmark. It specializes in quantum computing management software, offering solutions to address computational challenges across various industries such as life sciences, financial services, and logistics.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of major and rare diseases. It employs bioinformatics and artificial intelligence to mitigate risks and reduce costs and development timelines in traditional drug development, while its research and development is guided by a global team of experts in genetics, genomics, immunology, bioinformatics, and drug development.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of major and rare diseases. It employs bioinformatics and artificial intelligence to mitigate risks and reduce costs and development timelines in traditional drug development, while its research and development is guided by a global team of experts in genetics, genomics, immunology, bioinformatics, and drug development.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

Xenikos develops innovative immunotherapy medicines using anti-T-cell antibodies. These therapies aim to reset patients' immune systems quickly and efficiently, targeting activated adult T cells to improve treatment outcomes for serious immune diseases.

Gate2Brain is an early-stage biotechnology company dedicated to enhancing drug delivery across biological barriers, with a focus on improving treatments for brain diseases. The company's proprietary technology employs peptide-based innovations to facilitate drug transport across barriers like the blood-brain barrier, aiming to increase treatment efficiency and minimize side effects.

Vésale Pharma collaborates with renowned global research institutions to develop innovative healthcare solutions tailored for diverse populations. Their product portfolio spans dermatology, gastroenterology, women's health, immunity, and pregnancy, aiming to enhance overall well-being without adverse side effects.

ABCDx is a Geneva-based company that develops and validates biomarker panels and related diagnostics for brain injury care. It aims to identify patients at risk of severe long-term complications after traumatic brain injury or stroke and to educate clinicians on using these tests. The company is building a platform that analyzes brain biomarkers from a finger-prick blood sample to enable rapid, point-of-care diagnosis of brain injuries, supporting timely treatment decisions. Founded in 2014 by researchers from the University of Geneva and related institutes, ABCDx translates biomarker discovery and clinical validation into practical tools for stroke and brain injury management.

VIVAN Therapeutics pioneers personalized cancer therapeutics using innovative assay technology. It licenses technology from the Center for Personalized Cancer Therapeutics at Mount Sinai New York, offering a comprehensive, genomics-based drug screening service enabled by blockchain. The company's approach intelligently designs personalized treatments, combining cancer and non-cancer drugs to reduce toxicity and cost.

Actome specializes in developing emulsion coupling technology for life science research and personalized medicine. It uses proprietary technology to detect single protein molecules and protein interaction complexes, translating protein status into DNA barcodes using DNA-labeled antibodies.

Sightic Analytics specializes in developing AI-powered software that enables real-time analysis of drug effects through image analysis of the eye area. Utilizing a mobile phone's camera, the company's technology captures a short film sequence of an individual's eye, focusing on pupil responses to detect the presence of drugs. This innovative approach allows for efficient and discreet drug testing, making it suitable for use in various settings, including workplace environments. Sightic's solution aims to streamline the drug screening process while minimizing privacy concerns, enabling employers to monitor employee health effectively.

ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human models through advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed a suite of simulation tools known as Alya Red. This platform operates on a Software-as-a-Service model and is designed for the medical device and pharmaceutical industries. Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients, utilizing high-performance computing, computational biomechanics, and data analysis. These virtual avatars enable biomedical companies and healthcare professionals to enhance diagnostics, plan treatments, optimize drug delivery, and improve medical devices.

Founded in 2019, Arthex Biotech is a Spanish biotechnology company specializing in the development of antisense RNA therapies for genetic diseases. The company, spun off from the University of Valencia, leverages its team's expertise in drug discovery and microRNAs to create innovative treatments.

Founded in 2019, Arthex Biotech is a Spanish biotechnology company specializing in the development of antisense RNA therapies for genetic diseases. The company, spun off from the University of Valencia, leverages its team's expertise in drug discovery and microRNAs to create innovative treatments.

Founded in 2015, ATXA Therapeutics is an Irish pharmaceutical company dedicated to developing novel small molecule drugs for treating pulmonary arterial hypertension (PAH). With a strong scientific foundation and over €15 million in grant funding, the company focuses on advancing clinical trials and securing marketing authorization for its therapies.

Founded in 2015, ATXA Therapeutics is an Irish pharmaceutical company dedicated to developing novel small molecule drugs for treating pulmonary arterial hypertension (PAH). With a strong scientific foundation and over €15 million in grant funding, the company focuses on advancing clinical trials and securing marketing authorization for its therapies.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Celeris Therapeutics is an AI-first drug discovery company that focuses on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address high unmet medical needs in diseases like Parkinson's and various cancers. The company has created the Celeris One platform, which utilizes structure-based geometric deep learning to enhance the design and development of degraders by prioritizing specific E3 ligases, designing effective linkers, and selecting optimal compounds for synthesis. Additionally, Celeris Therapeutics operates an in-house automated laboratory that facilitates rapid generation of experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to discover and develop small-molecule degrader therapies across multiple therapeutic areas, while also advancing its own internal drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

ABCDx is a Geneva-based company that develops and validates biomarker panels and related diagnostics for brain injury care. It aims to identify patients at risk of severe long-term complications after traumatic brain injury or stroke and to educate clinicians on using these tests. The company is building a platform that analyzes brain biomarkers from a finger-prick blood sample to enable rapid, point-of-care diagnosis of brain injuries, supporting timely treatment decisions. Founded in 2014 by researchers from the University of Geneva and related institutes, ABCDx translates biomarker discovery and clinical validation into practical tools for stroke and brain injury management.

Actome specializes in developing emulsion coupling technology for life science research and personalized medicine. It uses proprietary technology to detect single protein molecules and protein interaction complexes, translating protein status into DNA barcodes using DNA-labeled antibodies.

ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human models through advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed a suite of simulation tools known as Alya Red. This platform operates on a Software-as-a-Service model and is designed for the medical device and pharmaceutical industries. Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients, utilizing high-performance computing, computational biomechanics, and data analysis. These virtual avatars enable biomedical companies and healthcare professionals to enhance diagnostics, plan treatments, optimize drug delivery, and improve medical devices.

Sightic Analytics specializes in developing AI-powered software that enables real-time analysis of drug effects through image analysis of the eye area. Utilizing a mobile phone's camera, the company's technology captures a short film sequence of an individual's eye, focusing on pupil responses to detect the presence of drugs. This innovative approach allows for efficient and discreet drug testing, making it suitable for use in various settings, including workplace environments. Sightic's solution aims to streamline the drug screening process while minimizing privacy concerns, enabling employers to monitor employee health effectively.

Qu&Co is a prominent startup specializing in quantum-computational algorithm and software development, focusing on optimizing specialty chemicals, pharmaceuticals, and functional materials. The company creates software that enhances in-house discovery and optimization processes by advancing innovative quantum-computational chemistry methods. This technology integrates seamlessly into existing chemistry and material-science workflows, allowing industries such as pharmaceuticals to conduct complex chemistry and multiphysics simulations on future quantum processors. In January 2022, Qu&Co merged with PASQAL, a leader in neutral atom-based quantum hardware, solidifying its position as a key player in the European quantum computing landscape.

Ovagen is a biotechnology company specializing in the commercial production of germ-free chicken eggs and birds. Primarily serving the pharmaceutical industry, Ovagen offers contract research services and expertise in specific poultry and rodent research technologies to Good Manufacturing Practice (GMP) standards.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

Celeris Therapeutics is an AI-first drug discovery company that focuses on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address high unmet medical needs in diseases like Parkinson's and various cancers. The company has created the Celeris One platform, which utilizes structure-based geometric deep learning to enhance the design and development of degraders by prioritizing specific E3 ligases, designing effective linkers, and selecting optimal compounds for synthesis. Additionally, Celeris Therapeutics operates an in-house automated laboratory that facilitates rapid generation of experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to discover and develop small-molecule degrader therapies across multiple therapeutic areas, while also advancing its own internal drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Abzu is a company that develops a scientific artificial intelligence platform aimed at accelerating drug discovery and bringing pharmaceuticals to market more efficiently. Founded in January 2018, with offices in Copenhagen, Denmark, and Barcelona, Spain, Abzu challenges traditional, opaque AI methods by utilizing its pioneering technology, the QLattice. This platform provides transparent and explainable models that enable data scientists to approach their work with a scientific mindset. By unlocking new disease mechanisms, discovering novel biomarkers, and designing improved drugs, Abzu empowers pharmaceutical and biotech companies to validate multiple targets simultaneously, thereby enhancing their research capabilities and reducing development costs.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

Elgan Pharma is a biotechnology company specializing in neonatology, primarily focused on addressing the medical challenges faced by premature infants. The company develops innovative therapies using nanotechnology aimed at preventing visual impairment, a significant concern for preterm babies. By targeting the multifactorial causes of visual disabilities, Elgan Pharma enables healthcare professionals to improve visual outcomes and reduce the risk of long-term disabilities in this vulnerable population. Through its advancements in late-stage development, the company is committed to enhancing the quality of care for premature infants and addressing critical developmental difficulties associated with their early birth.

Qubit Pharmaceuticals is a Paris-based drug discovery company established in 2020. It develops a simulation platform that reduces the cost and duration of preclinical development by using proprietary force field models and molecular dynamics to perform virtual screening and visualization, enabling the identification of viable drug candidates. The platform applies quantum physics-inspired modeling to support biopharmaceutical research and aims to translate advanced computational methods into practical tools for drug development.

Founded in 2017, Alkion BioInnovations specializes in developing natural plant active ingredients for pharmaceutical applications using proprietary semi-industrial technologies. The company focuses on environmentally friendly and consumer-beneficial products.

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden that focuses on developing innovative cell and gene therapies to treat cancer. The company’s portfolio includes four drug candidates: two oncolytic virus therapies, ELC-100 and ELC-201, and two CAR T-cell treatments, ELC-301 and ELC-401. Additionally, Elicera has developed a universal CAR T-cell technology platform named iTANK (ELC-001), designed to enhance the efficacy of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors. With its commitment to advancing immune-based cancer treatments, Elicera Therapeutics aims to improve outcomes for patients facing various forms of cancer.

Swiss Airtainer specializes in the design and production of temperature-controlled containers for air transportation of pharmaceuticals. Their innovative unit load device, designed to streamline the cold chain, ensures energy efficiency, precise temperature regulation, secure storage, and real-time connectivity, providing clients with a cost-effective and reliable solution for their temperature-sensitive cargo.

Nuclidium develops novel radiopharmaceutical tracers for cancer diagnostics. Its platform aims to detect specific target molecules on tumors, enabling more accurate staging and personalized treatment options.

Pasqal SAS, founded in 2019 and headquartered in Paris, France, specializes in the manufacture of quantum information processors utilizing atomic arrays. The company focuses on developing full-stack quantum computing technology that simulates complex phenomena to facilitate scientific discovery. Its innovative approach employs qubits made of neutral atoms organized in large two-dimensional and three-dimensional arrays, which enables analog computing. This technology addresses a variety of challenges, including optimization, drug discovery, and machine learning, empowering organizations to tackle complex problems across these fields.

BrainEver is a medical research company focused on developing innovative drugs for neurodegenerative disorders. Building on research by Alain Prochiantz and his team, BrainEver investigates the role of homeoproteins, which are essential for brain development and ongoing neuronal functions. The company hypothesizes that administering homeoproteins can enhance the physiological resilience of neurons and improve clinical symptoms in patients. Among its drug candidates, Engrailed 1 (BREN01) is the most advanced, aimed at treating Parkinson Disease and Amyotrophic Lateral Sclerosis (ALS). Additionally, BrainEver is actively developing a pipeline of four more drug candidates targeting other neurodegenerative conditions, including Huntington Disease and Optic Neuropathies. Through its research and development efforts, BrainEver seeks to provide effective therapeutic options for healthcare practitioners and their patients.

Aplagon is a biopharmaceutical company focused on the development of innovative antithrombotic compounds aimed at addressing unmet medical needs in patients experiencing complications from vascular interventions. The company specializes in creating biological mimetics of heparin proteoglycan, which are designed to effectively manage thrombotic occlusions and ischemic reperfusion injuries associated with vascular injuries. By prioritizing safety and efficacy, Aplagon seeks to deliver antithrombotic therapies that offer significant advantages over existing treatments, ultimately improving patient outcomes in challenging medical scenarios.

Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies, particularly focusing on kinase inhibitors. The company explores natural marine substances as a foundation for its drug discovery efforts, optimizing molecules derived from marine organisms. Perha Pharmaceuticals aims to address significant medical challenges, including the prevention of cisplatin-induced hearing loss and the treatment of cognitive disorders associated with Down syndrome and Alzheimer's disease. Through its targeted approach, the company seeks to provide effective solutions for patients suffering from hearing loss and related cognitive impairments.

Ovagen is a biotechnology company specializing in the commercial production of germ-free chicken eggs and birds. Primarily serving the pharmaceutical industry, Ovagen offers contract research services and expertise in specific poultry and rodent research technologies to Good Manufacturing Practice (GMP) standards.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

NeuroKaire develops personalized psychiatry testing tools. It uses innovative technology to predict the most effective drug treatment for patients, enabling faster recovery, fewer side effects, and lower dosing.

Aplagon is a biopharmaceutical company focused on the development of innovative antithrombotic compounds aimed at addressing unmet medical needs in patients experiencing complications from vascular interventions. The company specializes in creating biological mimetics of heparin proteoglycan, which are designed to effectively manage thrombotic occlusions and ischemic reperfusion injuries associated with vascular injuries. By prioritizing safety and efficacy, Aplagon seeks to deliver antithrombotic therapies that offer significant advantages over existing treatments, ultimately improving patient outcomes in challenging medical scenarios.

Nagi Bioscience develops automated testing devices that use Caenorhabditis elegans worms to screen molecules for pharmaceutical, chemical and cosmetic applications. Its Organism-on-Chip platform combines whole-organism biology with an automated in vitro workflow for culture, treatment, and multi-parametric analysis, enabling toxicity testing, drug discovery, and anthelmintic screening. The technology links in vivo worm models with a fully automated platform to observe biological responses that emerge at the whole-organism level. The company is headquartered in Lausanne, Switzerland.

Betalin Therapeutics is a privately-held company dedicated to developing innovative cell therapy solutions for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. This platform combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. The EMP aims to offer an alternative to traditional insulin therapy, potentially eliminating the need for insulin injections and glucose monitoring in patients. Following promising in-vitro and preliminary in-vivo results, Betalin Therapeutics is focused on optimizing the therapy using animal models and preparing to submit an Investigational New Drug (IND) application to the FDA in anticipation of advancing to clinical trials.

Founded in 2017, Alkion BioInnovations specializes in developing natural plant active ingredients for pharmaceutical applications using proprietary semi-industrial technologies. The company focuses on environmentally friendly and consumer-beneficial products.

Filterlex Medical is a medical device company focused on cardiovascular embolic protection. It develops embolic protection devices to reduce the risk of stroke and other embolic complications during catheter-based structural heart procedures, including transcatheter aortic valve implantation. Its CAPTIS full-body embolic protection device is designed for intuitive deployment and retrieval and is compatible with multiple catheter sizes, enabling integration into existing workflows. The company aims to improve patient safety during minimally invasive heart valve replacement procedures. It was founded in 2015 and is based in Yokneam, Israel.

VBL Therapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel treatments for cancer and immune-inflammatory diseases. The company utilizes two proprietary platform technologies that harness the body's natural physiological and genetic regulatory elements. Its lead product candidate, VB-111, is a gene-based biologic aimed at treating solid tumors, specifically recurrent glioblastoma, an aggressive form of brain cancer. In addition to its oncology efforts, VBL Therapeutics is pursuing programs that target anti-inflammatory diseases, leveraging its Lecinoxoid platform technology. The company's diverse portfolio reflects its commitment to advancing innovative therapeutic solutions in the biopharmaceutical landscape.

VBL Therapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel treatments for cancer and immune-inflammatory diseases. The company utilizes two proprietary platform technologies that harness the body's natural physiological and genetic regulatory elements. Its lead product candidate, VB-111, is a gene-based biologic aimed at treating solid tumors, specifically recurrent glioblastoma, an aggressive form of brain cancer. In addition to its oncology efforts, VBL Therapeutics is pursuing programs that target anti-inflammatory diseases, leveraging its Lecinoxoid platform technology. The company's diverse portfolio reflects its commitment to advancing innovative therapeutic solutions in the biopharmaceutical landscape.

Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies, particularly focusing on kinase inhibitors. The company explores natural marine substances as a foundation for its drug discovery efforts, optimizing molecules derived from marine organisms. Perha Pharmaceuticals aims to address significant medical challenges, including the prevention of cisplatin-induced hearing loss and the treatment of cognitive disorders associated with Down syndrome and Alzheimer's disease. Through its targeted approach, the company seeks to provide effective solutions for patients suffering from hearing loss and related cognitive impairments.

Founded in 2019, EVerZom is a Paris-based biotech company specializing in nanomedicine. It develops and manufactures extracellular vesicles (exosomes, microvesicles, apoptotic bodies) at commercial scale under Good Manufacturing Practice (GMP) standards for pharmaceutical applications in regenerative medicine and drug delivery.

Tada Group AB, founded in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacturing of medical products, primarily focusing on intravenous solutions. The company offers products such as the Thoor infusion tube, which is designed for efficiency in medical applications. Additionally, Tada Group has developed the ReLink connector, an innovative solution aimed at minimizing complications and costs related to accidental disconnections in IV lines, which is a significant issue in both hospital and homecare environments. Through its product offerings, Tada Group addresses critical challenges in healthcare, enhancing safety and reliability in infusion practices.

Allero Therapeutics is a biopharmaceutical company developing immunotherapies for immune-mediated disorders. Its core technology, Specific Oromucosal Immunotherapy (SOMIT), enables targeted delivery of antigen-specific therapies to restore immune tolerance.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, focused on the development and manufacturing of therapeutic proteins aimed at restoring blood clotting in patients experiencing bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X that can promptly reinstate blood clotting in patients using direct factor Xa anticoagulants, such as rivaroxaban, apixaban, and edoxaban. These anticoagulants, commonly prescribed for the prevention and treatment of thrombosis and stroke, often lead to severe bleeding as a side effect. PseudoXa addresses this critical issue by effectively stopping and preventing bleeding, thereby enhancing the safety of anticoagulant therapy for millions of patients worldwide.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, focused on the development and manufacturing of therapeutic proteins aimed at restoring blood clotting in patients experiencing bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X that can promptly reinstate blood clotting in patients using direct factor Xa anticoagulants, such as rivaroxaban, apixaban, and edoxaban. These anticoagulants, commonly prescribed for the prevention and treatment of thrombosis and stroke, often lead to severe bleeding as a side effect. PseudoXa addresses this critical issue by effectively stopping and preventing bleeding, thereby enhancing the safety of anticoagulant therapy for millions of patients worldwide.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Palobiofarma is a Spanish biotechnology company based in Barcelona, focused on discovering and developing new medicines by modulating adenosine receptors. It aims to be a leader in European adenosine receptor drug discovery, using medicinal chemistry and in vitro pharmacology to identify selective adenosine receptor modulators, with potential applications in treating advanced prostate cancer.

Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

LiMM Therapeutics is a biopharmaceutical company focused on developing innovative therapeutic agents aimed at preserving health and addressing inflammatory, infectious, and metabolic diseases. The company leverages the molecular interactions between neuronal cells and innate lymphoid cells to create products that regulate immune responses and combat infections. By bridging advancements in neural sensing and immunology, LiMM Therapeutics aims to unlock new therapeutic solutions that can significantly benefit patients. Its research emphasizes the neuronal-derived regulation of immune cell activity within peripheral tissues, contributing to the development of a robust pipeline of novel treatments.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Op2Lysis is a biotechnology company focused on developing innovative treatments for hemorrhagic stroke. The company specializes in a thrombolytic drug designed to dissolve intracerebral hematomas, which are blood clots that can lead to significant disability if not addressed. This drug utilizes vectorization technology and is intended to be administered locally through a catheter, allowing for micro-invasive surgical procedures. By effectively liquefying the hematoma, Op2Lysis aims to provide patients with a safer alternative to major surgeries, thereby improving recovery outcomes and reducing long-term disabilities associated with hemorrhagic strokes.

Fibriant is a biotechnology company specializing in the development and production of recombinant fibrinogen, a protein crucial for blood clotting, tissue repair, and infection defense.

Op2Lysis is a biotechnology company focused on developing innovative treatments for hemorrhagic stroke. The company specializes in a thrombolytic drug designed to dissolve intracerebral hematomas, which are blood clots that can lead to significant disability if not addressed. This drug utilizes vectorization technology and is intended to be administered locally through a catheter, allowing for micro-invasive surgical procedures. By effectively liquefying the hematoma, Op2Lysis aims to provide patients with a safer alternative to major surgeries, thereby improving recovery outcomes and reducing long-term disabilities associated with hemorrhagic strokes.

Fibriant is a biotechnology company specializing in the development and production of recombinant fibrinogen, a protein crucial for blood clotting, tissue repair, and infection defense.

Palobiofarma is a Spanish biotechnology company based in Barcelona, focused on discovering and developing new medicines by modulating adenosine receptors. It aims to be a leader in European adenosine receptor drug discovery, using medicinal chemistry and in vitro pharmacology to identify selective adenosine receptor modulators, with potential applications in treating advanced prostate cancer.

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company focused on inflammatory disorders by strengthening epithelial barrier integrity, a key factor in the progression of diseases affecting the skin, lungs, intestinal tract, and genital tract. It develops proprietary, orally available macrolide drug candidates with potential as first-in-class, disease-modifying therapies for chronic respiratory diseases and other significant unmet medical needs. Its lead candidate, EP395, aims to be the first oral, non-antibiotic macrolide that reinforces barrier function and provides anti-inflammatory effects for COPD and related inflammatory airway conditions.

RemedyBio is an Irish biotechnology company specializing in immunology-focused drug discovery and development. It has pioneered innovative approaches to understanding the immune system and identifying new therapies.